Eupraxia Pharmaceuticals ... (EPRX)
3.02
-0.03 (-0.98%)
At close: Jan 15, 2025, 1:14 PM
undefined% (undefined)
| Bid | 2.92 |
| Market Cap | 107.58M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.93 |
| PE Ratio (ttm) | -3.25 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.08 |
| Volume | 27,136 |
| Avg. Volume (20D) | 16,927 |
| Open | 3.00 |
| Previous Close | 3.05 |
| Day's Range | 2.84 - 3.02 |
| 52-Week Range | 2.20 - 4.08 |
| Beta | undefined |
About EPRX
A detailed description of the company is not yet available....
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 29
Stock Exchange NASDAQ
Ticker Symbol EPRX
Analyst Forecast
According to 1 analyst ratings, the average rating for EPRX stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 198.01% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
+10.43%
Eupraxia Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
7 months ago ·
Source
+2.43%
Eupraxia Pharmaceuticals shares are trading higher after the company announced data from its Phase 1b/2a RESOLVE trial showing 'tolerability and extended signals of potential efficacy out to 24 weeks without meaningful side effects.'